Targovax ASA Strengthens Management with Lubor Gaal as Chief Financial Officer
Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has appointed Dr. Lubor Gaal as Chief Financial Officer (CFO), effective as of 7 March 2022.
Dr. Lubor Gaal is a seasoned industry executive with 25 years of experience working in large pharmaceutical and biotechnology companies in Europe and the USA. Most recently, he served as Managing Director and Head of Europe at Locust Walk, a global life science boutique investment bank. At Locust Walk, Dr. Gaal was responsible for overseeing all European strategic transactions, including financings, M&A and licensing. Before Locust Walk, he was Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall and Head of Europe Search and Evaluation for oncology at Bristol-Myers Squibb. Prior to that, Dr. Gaal held executive management positions at Neuro3d and Vectron Therapeutics, and global business development roles in Bayer. Dr. Gaal has a Ph.D. in molecular and cell biology from the University of California at Berkeley, USA.
In Targovax, Dr. Gaal´s core responsibilities will be to oversee all financial, investor relations and business development activities, as well as playing an integral role in defining and executing the corporate strategy.
Dr. Erik Digman Wiklund, CEO, commented: “We are extremely pleased to have attracted an individual of Lubor´s caliber to Targovax. Lubor has deep experience in business development, commercial and advisory roles in both big pharma and development-stage biotech companies, and, importantly, brings access to his broad, international industry network into Targovax. With the addition of Lubor, we have now established a world-class management team ready to execute on our clinical program, pipeline development and corporate strategy.”
Dr. Lubor Gaal added: “Targovax has built a strong clinical portfolio, and I am very excited to join the team to help bring their innovative cancer immunotherapy pipeline to fruition. In my opinion, the class-leading clinical stage ONCOS-102 asset combined with the emerging circular RNA program puts Targovax in a unique position for success. I have previously had the pleasure to work with Targovax in an advisory role and experienced the quality and strength of both the science and the people, and now I really look forward to become a member of the organization.”
Dr. Gaal will join Targovax as CFO on 7 March 2022.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more